Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16151631rdf:typepubmed:Citationlld:pubmed
pubmed-article:16151631lifeskim:mentionsumls-concept:C1882726lld:lifeskim
pubmed-article:16151631lifeskim:mentionsumls-concept:C0243192lld:lifeskim
pubmed-article:16151631lifeskim:mentionsumls-concept:C0022116lld:lifeskim
pubmed-article:16151631lifeskim:mentionsumls-concept:C0035126lld:lifeskim
pubmed-article:16151631lifeskim:mentionsumls-concept:C0255998lld:lifeskim
pubmed-article:16151631lifeskim:mentionsumls-concept:C0205409lld:lifeskim
pubmed-article:16151631lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:16151631lifeskim:mentionsumls-concept:C1707127lld:lifeskim
pubmed-article:16151631pubmed:issue5lld:pubmed
pubmed-article:16151631pubmed:dateCreated2005-9-9lld:pubmed
pubmed-article:16151631pubmed:abstractTextIschemia/reperfusion injury during liver transplantation is a major cause of primary nonfunctioning graft for which there is no effective treatment other than retransplantation. Adenosine prevents ischemia-reperfusion-induced hepatic injury via its A2A receptors. The aim of this study was to investigate the role of A2A receptor agonist on apoptotic ischemia/reperfusion-induced hepatic injury in rats. Isolated rat livers within University of Wisconsin solution were randomly divided into four groups: (1) continuous perfusion of Krebs-Henseleit solution through the portal vein for 165 minutes (control); (2) 30-minute perfusion followed by 120 minutes of ischemia and 15 minutes of reperfusion; (3) like group 2, but with the administration of CGS 21680, an A2A receptor agonist, 30 microg/100 ml, for 1 minute before ischemia; (4) like group 3, but with administration of SCH 58261, an A2A receptor antagonist. Serum liver enzyme levels were measured by biochemical analysis, and intrahepatic caspase-3 activity was measured by fluorometric assay; apoptotic cells were identified by morphological criteria, the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) fluorometric assay, and immunohistochemistry for caspase-3. Results showed that at 1 minute of reperfusion, there was a statistically significant reduction in liver enzyme levels in the animals pretreated with CGS (p < 0.05). On fluorometric assay, caspase-3 activity was significantly decreased in group 3 compared to group 2 (p < 0.0002). The reduction in postischemic apoptotic hepatic injury in the CGS-treated group was confirmed morphologically, by the significantly fewer apoptotic hepatocyte cells detected (p < 0.05); immunohistochemically, by the significantly weaker activation of caspase-3 compared to the ischemic group (p < 0.05); and by the TUNEL assay (p < 0.05). In conclusion, the administration of A2A receptor agonist before induction of ischemia can attenuate postischemic apoptotic hepatic injury and thereby minimize liver injury. Apoptotic hepatic injury seems to be mediated through caspase-3 activity.lld:pubmed
pubmed-article:16151631pubmed:languageenglld:pubmed
pubmed-article:16151631pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16151631pubmed:citationSubsetIMlld:pubmed
pubmed-article:16151631pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16151631pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16151631pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16151631pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16151631pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16151631pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16151631pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16151631pubmed:statusMEDLINElld:pubmed
pubmed-article:16151631pubmed:monthOctlld:pubmed
pubmed-article:16151631pubmed:issn1360-8185lld:pubmed
pubmed-article:16151631pubmed:authorpubmed-author:VidneB ABAlld:pubmed
pubmed-article:16151631pubmed:authorpubmed-author:PappaAAlld:pubmed
pubmed-article:16151631pubmed:authorpubmed-author:HochhauserEElld:pubmed
pubmed-article:16151631pubmed:authorpubmed-author:SulkesJJlld:pubmed
pubmed-article:16151631pubmed:authorpubmed-author:Ben-AriZZlld:pubmed
pubmed-article:16151631pubmed:authorpubmed-author:CheporkoYYlld:pubmed
pubmed-article:16151631pubmed:issnTypePrintlld:pubmed
pubmed-article:16151631pubmed:volume10lld:pubmed
pubmed-article:16151631pubmed:ownerNLMlld:pubmed
pubmed-article:16151631pubmed:authorsCompleteYlld:pubmed
pubmed-article:16151631pubmed:pagination955-62lld:pubmed
pubmed-article:16151631pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:16151631pubmed:meshHeadingpubmed-meshheading:16151631...lld:pubmed
pubmed-article:16151631pubmed:meshHeadingpubmed-meshheading:16151631...lld:pubmed
pubmed-article:16151631pubmed:meshHeadingpubmed-meshheading:16151631...lld:pubmed
pubmed-article:16151631pubmed:meshHeadingpubmed-meshheading:16151631...lld:pubmed
pubmed-article:16151631pubmed:meshHeadingpubmed-meshheading:16151631...lld:pubmed
pubmed-article:16151631pubmed:meshHeadingpubmed-meshheading:16151631...lld:pubmed
pubmed-article:16151631pubmed:meshHeadingpubmed-meshheading:16151631...lld:pubmed
pubmed-article:16151631pubmed:meshHeadingpubmed-meshheading:16151631...lld:pubmed
pubmed-article:16151631pubmed:meshHeadingpubmed-meshheading:16151631...lld:pubmed
pubmed-article:16151631pubmed:meshHeadingpubmed-meshheading:16151631...lld:pubmed
pubmed-article:16151631pubmed:meshHeadingpubmed-meshheading:16151631...lld:pubmed
pubmed-article:16151631pubmed:meshHeadingpubmed-meshheading:16151631...lld:pubmed
pubmed-article:16151631pubmed:meshHeadingpubmed-meshheading:16151631...lld:pubmed
pubmed-article:16151631pubmed:year2005lld:pubmed
pubmed-article:16151631pubmed:articleTitleEffect of adenosine A2A receptor agonist (CGS) on ischemia/reperfusion injury in isolated rat liver.lld:pubmed
pubmed-article:16151631pubmed:affiliationLiver Institute and Department of Medicine D, Rabin Medical Center, Beilinson Campus, Petah Tiqva 49100, Israel. gbenari@bezeqint.netlld:pubmed
pubmed-article:16151631pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16151631pubmed:publicationTypeIn Vitrolld:pubmed